CSL's Financial Results
CSL's Half Year financial results were announced on Wednesday, 12th February 2020. Please click the link below to view our historic Full Year and Half Year Financial Results.More Information
Search Results144 results found
We have announced our 2019 Half Year Results.
We will announced our 2020 Half Year Results on Wednesday, 12th February 2020 (AEDT)
DEAR SHAREHOLDER I am pleased to report a solid performance for our half year result.
For immediate release 13 February 2019 Half Year Result 20191
CSL's exceptionally strong performance is a result of the focused execution of our strategy. Learn more.
Explanation of results For further explanation of the results please refer to the accompanying press release and "Review of Operations" in the Directors' Report that is within the Half-year Report.
Release of Half Year From end of relevant half year From 4 weeks before release** Results to ASX until the start of the trading day until the start of the trading day following the release following the release
A strong half year for CSL with revenue up 11%1 and net profit after tax up 11%1 reflecting: •
We have now completed Phase 1 for CSL346 with planning underway for Phase 2a Proof of Concept study in patients with diabetic nephropathy to be initiated in the first half of next year. •
The role of CSL's internal audit function is to provide Prior to giving their directors' declaration in respect of the independent and objective assurance to the Audit and annual and half-year financial statements, the Board requires Risk Management Committee and executive management the Managing Director and the chief financial officer to regarding the effectiveness of CSL's risk management each sign a written declaration to the Board to the effect processes (including the state of any material risks) and that, in their opinion the financial records of the entity have internal compliance and control systems.